Objective: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. Method: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). Results: Ten (n = 3006) trials were included in the analyses. We observed statistical differences for the following outcomes: decreased appetite between atomoxetine and placebo (odds ratio [OR] = 0.15, 95% credibility interval [CrI] = [0.05, 0.38]) and extended-release mixed amphetamine salts and placebo (OR = 0.06, 95% CrI = [0.00, 0.51]); insomnia between atomoxetine and placebo (OR = 0.48, 95% CrI = [0.27, 0.88]) and extended-release mixed amphetamine salts and placebo (OR = 0.23, 95% CrI = [0.06, 0.76]); sleepiness between atomoxetine and methylphenidate OROS (OR = 0.24, 95% CrI = [0.06, 0.97]); and decreased libido between atomoxetine and placebo (OR = 0.28, 95% CrI = [0.08, 0.90]). Conclusion: It was possible to generate evidence about the safety profile of different ADHD drugs.
AdlerL. A.DirksB.DeasP. F.RaychaudhuriA.DauphinM. R.LasserR. A.WeislerR. H. (2013). Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: Results from a randomized, double-blind, placebo-controlled study. Journal Clinical Psychiatry, 74, 694-702. doi:10.4088/JCP.12m08144
2.
AdlerL. A.SpencerT.BrownT. E.HoldnackJ.SaylorK.SchuhK.. . . KelseyD. (2009). Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder. A 6-month, double-blind trial. Journal of Clinical Psychopharmacology, 29, 44-50. doi:10.1097/JCP.0b013e318192e4a0
3.
AdlerL. A.ZimmermanB.StarrH. L.SilberS.PalumboJ.OrmanC.SpencerT. (2009). Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. Journal of Clinical Psychopharmacology, 29, 239-247. doi:10.1097/JCP.0b013e3181a390ce
4.
AlshammariT. M. (2016). Drug safety: The concept, inception and its importance in patients’ health. Saudi Pharmaceutical Journal, 24, 405-412. doi:10.1016/j.jsps.2014.04.008
AmiriS.FarhangS.GhoreishizadehM. A.MalekA.MohammadzadehS. (2012). Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder. Human Psychopharmacology, 27, 76-81. doi:10.1002/hup.1274
7.
ArnoldV. K.FeifelD.EarlC. Q.YangR.AdlerL. A. (2014). A 9-week, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of modafinil as treatment for adults with ADHD. Journal of Attention Disorder, 18, 133-144. doi:10.1177/1087054712441969
8.
Bolea-AlamañacB.NuttD. J.AdamouM.AshersonP.BazireS.CoghillD.. . . YoungS. J. (2014). Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28, 179-203. doi:10.1177/0269881113519509
9.
BusheC.DayK.ReedV.KarlsdotterK.BerggrenL.PitcherA.. . . HaynesV. (2016). A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients. Journal of Psychopharmacology, 30, 444-458. doi:10.1177/0269881116636105
10.
ButterfieldM. E.SaalJ.YoungB.YoungJ. L. (2016). Supplementary guanfacina hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study. Psychiatry Research, 236, 136-141. doi:10.1016/j.psychres.2015.12.017
11.
BymasterF. P.KatnerJ. S.NelsonD. L.Hemrick-LueckeS. K.ThrelkeldP. G.HeiligensteinJ. H.. . . PerryK. W. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711. doi:10.1016/S0893-133X(02)00346-9
12.
CaldwellD. M.WeltonN. J.AdesA. E. (2010). Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. Journal of Clinical Epidemiology, 63, 875-882. doi:10.1016/j.jclinepi.2009.08.025
13.
CamporealeA.DayK. A.RuffD.ArsenaultJ.WilliamsD.KelseyD. K. (2013). Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: A pooled analysis. Drug Safety, 36, 663-671. doi:10.1007/s40264-013-0074-2
14.
CamporealeA.PorsdalV.BruyckereK.TanakaY.UpadhyayaH.DeixC.DeberdtW. (2015). Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: An integrated analysis of 15 clinical trials. Journal of Psychopharmacology, 29, 3-14. doi:10.1177/0269881114560183
Canadian Attention Deficit Hyperactivitiy Disorder Resource Alliance. (2011). Canadian ADHD Practice guidelines (CAP) guidelines (3rd ed.). Toronto, Ontario: Author. Retrieved from http://www.caddra.ca/cms4/pdfs/caddraGuidelines2011.pdf
17.
ChanE.FoglerJ. M.HammernessP. G. (2016). Treatment of attention-deficit/hyperactivity disorder in adolescents: A systematic review. Journal of the American Medical Association, 315, 1997-2008. doi:10.1001/jama.2016.5453
18.
ChiaraD. G.BassareoV.FenuS.LucaM. A.SpinaL.CadoniC.. . . LeccaD. (2004). Dopamine and drug addiction: The nucleus accumbens shell connection. Neuropharmacology, 47, 227-241. doi:10.1016/j.neuropharm.2004.06.032
19.
DiasS.WeltonN. J.CaldwellD. M.AdesA. E. (2010). Checking consistency in mixed treatment comparison meta-analysis. Statistic in Medicine, 29, 932-944. doi:10.1002/sim.3767
20.
DulcanM. K.BensonR. S. (1997). Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with ADHD. Journal of the American Academy of Child & Adolescent Psychiatry, 36, 1311-1317. doi:10.1097/00004583-199709000-00033
21.
EvansD. (2003). Hierarchy of evidence: A framework for ranking evidence evaluating healthcare interventions. Journal of Clinical Nursing, 12, 77-84. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12519253
22.
GibsonA. P.BettingerT. L.PatelN. C.CrismonM. L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Annals of Pharmacotherapy, 40, 1134-1142. doi:10.1345/aph.1G582
23.
GotoT.HirataY.TakitaY.TrzepaczP. T.AllenA. J.SongD. H.. . . TakahashiM. (2017). Efficacy and safety of atomoxetine hydrochloride in Asian adults with ADHD: A multinational 10-week randomized double-blind placebo-controlled Asian study. Journal of Attention Disorder, 21, 100-109. doi:10.1177/1087054713510352
24.
HamediM.MohammadiM.GhaleihaA.KeshavarziZ.JafariniaM.KeramatfarR.. . . AkhondzadehS. (2014). Bupropion in adults with attention-deficit/hyperactivity disorder: A randomized, double-blind study. Acta Medica Iranica, 52, 675-680. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/25325205
25.
HigginsJ. P. T.GreenS. (2011). Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration. Available from http://handbook.cochrane.org/
26.
Huedo-MedinaT. B.Sánchez-MecaJ.Marín-MartínezF.BotellaJ. (2006). Assessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychological Methods, 11, 193-206. doi:10.1037/1082-989X.11.2.193
27.
JansenJ. P.CrawfordB. M.BergmanG.StamW. (2008). Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons. Value in Health, 11, 956-964. doi:10.1111/j.1524-4733.2008.00347.x
28.
JansenJ. P.NaciH. (2013). Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine, 11(159), 1-8. doi:10.1186/1741-7015-11-159
29.
KesslerR. C.AdlerL.BarkleyR.BiedermanJ.ConnersC. K.DemlerO.. . . ZaslavskyA. M. (2006). The prevalence and correlates of adult ADHD in the United States: Results from the national comorbidity survey replication. The American Journal of Psychiatry, 163, 716-723. doi:10.1176/appi.ajp.163.4.716
30.
KoblanK. S.HopkinsS. C.SarmaK.JinF.GoldmanR.KollinsS. H.LoebelA. (2015). Dasotraline for the treatment of attention-deficit/hyperactivity disorder: A randomized, double-blind, placebo-controlled, proof-of-concept trial in adults. Neuropsychopharmacology, 40, 2745-2752. doi:10.1038/npp.2015.124
31.
LolandC. J.MereuM.OkunolaO. M.CaoJ.PrisinzanoT. E.MazierS.. . . NewmanA. H. (2012). R-modafinil (armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biological Psychiatry, 72, 405-413. doi:10.1016/j.biopsych.2012.03.022
32.
ManorI.Ben-HayunR.Aharon-PeretzJ.SalomyD.WeizmanA.DanielyY.. . . AdlerL. A. (2012). A randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of extended-release metadoxine in adults with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 73, 1517-1523. doi:10.4088/JCP.12m07767
33.
MichelsonD.AdlerL.SpencerT.ReimherrF. W.WestS. A.AllenA. J.. . . MiltonD. (2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/12547466
34.
MillsteinR. B.WilensT. E.BiedermanJ.SpencerT. J. (1997). Presenting ADHD symptoms and subtypes in clinically referred adults with ADHD. Journal of Attention Disorder, 2, 159-166. doi:10.1177/108705479700200302
35.
MooreR. A.CarrollD.JenkinsonC.ReynoldsD. J.GavaghanD. J.McQuayH. J. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 17, 1-12. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/8721797
36.
PalumboD. R.SalleeF. R.PelhamW. E.BuksteinO. G.DavissW. B.McDermottM. P. (2008). Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. Journal of the American Academy of Child & Adolescent Psychiatry, 47, 180-188. doi:10.1097/chi.0b013e31815d9af7
37.
PatersonR.DouglasC.HallmayerJ.HaganM.KrupeniaZ. (1999). A randomised, double-blind, placebo-controlled trial of dexamphetamine in adults with attention deficit hyperactivity disorder. Australian & New Zealand Journal of Psychiatry, 33, 494-502. doi:10.1080/j.1440-1614.1999.00590.x
38.
PotterA. S.RyanK. K.NewhouseP. A. (2009). Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). Human Psychopharmacology, 24, 309-317. doi:10.1002/hup.1026
39.
RiahiF.Tehrani-DoostM.ShahrivarZ.Alaghband-RadJ. (2010). Efficacy of reboxetine in adults with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled clinical trial. Human Psychopharmacology, 25, 570-576. doi:10.1002/hup.1158
40.
SampaioR. F.ManciniM. C. (2007). Estudos de Revisão Sistemática: Um guia para síntese criteriosa da evidência científica [Systematic review studies: A guide for judicious synthesis of scientific evidence]. Revista Brasileira de Fisioterapia, 11, 83-89. doi:10.1590/S1413-35552007000100013
41.
SimonV.CzoborP.BálintS.MészárosA.BitterI. (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. The British Journal of Psychiatry, 194, 204-211. doi:10.1192/bjp.bp.107.048827
42.
SpencerT. J.AdlerL. A.McGoughJ. J.MunizR.JiangH.PestreichL. (2007). Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder. Biological Psychiatry, 61, 1380-1387. doi:10.1016/j.biopsych.2006.07.032
43.
SpencerT. J.AdlerL. A.WeislerR. H.YouchaS. H. (2008). Triple-bead mixed amplhetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: A randomized, double-blind, multicenter, placebo-controlled study. The Journal of Clinical Psychiatry, 69, 1437-1448. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/19012813
44.
SugrueD.BognerR.EhretM. J. (2014). Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder. American Journal of Health-System Pharmacy, 71, 1163-1170. doi:10.2146/ajhp130638
45.
SumnerC. R.SchuhK. J.SuttonV. K.LipetzR.KelseyD. K. (2006). Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis. Journal of Child and Adolescent Psychopharmacology, 16, 699-711. doi:10.1089/cap.2006.16.699
46.
SutherlandS. M.AdlerL. A.ChenC.SmithM. D.FeltnerD. E. (2012). An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. The Journal of Clinical Psychiatry, 73, 445-450. doi:10.4088/JCP.10m06788
47.
TakahashiN.KohT.TominagaY.SaitoY.KashimotoY.MatsumuraT. (2014). A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan. The World Journal of Biological Psychiatry, 15, 488-498. doi:10.3109/15622975.2013.868925
ViktrupL.PangalloB. A.DetkeM. J.ZinnerN. R. (2004). Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence. The Primary Care Companion to the Journal of Clinical Psychiatry, 6(2), 65-73. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC427601/
51.
WeislerR. H.BiedermanJ.SpencerT. J.WilensT. E.FaraoneS. V.ChrismanA. K.. . . TullochS. J. (2006). Mixed amphetamine salts extended-release in the treatment of adult ADHD: A randomized, controlled trial. CNS Spectrums, 11, 625-639. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16871129
52.
WeislerR. H.PandinaG. J.DalyE. J.CooperK.Gassmann-MayerC. (2012). Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs, 26, 421-434. doi:10.2165/11631990-000000000-00000
53.
WilensT. E.BiedermanJ.FaraoneS. V.MartelonM.WesterbergD.SpencerT. J. (2009). Presenting ADHD symptoms, subtypes, and comorbid disorders in clinically referred adults with ADHD. The Journal of Clinical Psychiatry, 70, 1557-1562. doi:10.4088/JCP.08m04785pur
54.
WilensT. E.BiedermanJ.PrinceJ.SpencerT. J.FaraoneS. V.WarburtonR.. . . GellerD. (1996). Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. The American Journal of Psychiatry, 153, 1147-1153. doi:10.1176/ajp.153.9.1147
55.
YoungJ. L.SarkisE.QiaoM.WietechaL. (2011). Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: A 24-weeek, randomized, double-blind, placebo-controlled trial. Clinical Neuropharmacology, 34(2), 51-60. doi:10.1097/WNF.0b013e31820c00eb
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
